Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

Paul Goepfert, Bo Fu, Anne-Laure Chabanon, Matthew Bonaparte, Matthew Davis, Brandon Essink, Ian Frank, Owen Haney, Helene Janosczyk, Michael C. Keefer, Marguerite Koutsoukos, Murray Kimmel, Roger Masotti, Stephen J. Savarino, Lode Schuerman, Howard Schwartz, Lawrence Sher, Jon Smith, Fernanda Tavares Da Silva, Sanjay Gurunathan, Carlos A. DiazGranados, Guy de Bruyn